Boston Scientific (NYSE:BSX) Issues Quarterly Earnings Results

Boston Scientific (NYSE:BSX) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.01, FiscalAI reports. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.06 billion. Boston Scientific’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 EPS.

Here are the key takeaways from Boston Scientific’s conference call:

• Q3 missed expectations: Organic revenue grew 1.5%, below the 3%–5% outlook, while adjusted EPS fell 3% to $0.73. The cybersecurity incident reduced revenue growth by roughly 300 basis points and EPS by approximately $0.07.
• Boston Scientific expects continued near-term pressure, guiding to a 1%–3% organic revenue decline and adjusted EPS of $0.77–$0.79 in Q4. Management said 2027 revenue and EPS growth will be challenging as EP and WATCHMAN face market-share and competitive pressures, while China pricing headwinds intensify.
• WATCHMAN sales declined 6% and EP sales declined 5% in Q3, with further EP share erosion expected until new products launch. The company also cited weaker urology performance, China-related pricing pressure, supply constraints, and delays affecting parts of its product pipeline.
• Management expects a return to stronger performance in 2028, supported by launches including FARAWAVE Ultra, 2D ICE, CRM’s Denali platform, new IVL and imaging technologies, and a potential Penumbra contribution. The company identified approximately $25 billion of new market opportunities by 2030.
• A company-wide restructuring program is expected to generate more than $500 million in savings over three years, with over half anticipated by the end of 2027. Boston Scientific said the program should improve operating leverage while preserving investment in key growth platforms.

Boston Scientific Stock Down 7.9%

Boston Scientific stock traded down $3.55 during midday trading on Wednesday, reaching $41.51. The company’s stock had a trading volume of 22,892,086 shares, compared to its average volume of 18,425,303. Boston Scientific has a fifty-two week low of $39.57 and a fifty-two week high of $105.65. The business has a 50-day simple moving average of $45.29 and a 200-day simple moving average of $57.71.

Analyst Ratings Changes

BSX has been the subject of a number of analyst reports. Stifel Nicolaus reduced their price objective on shares of Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Monday. Raymond James Financial reissued an “outperform” rating and issued a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research note on Thursday, July 30th. Evercore cut their price objective on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 7th. Piper Sandler reduced their price target on Boston Scientific from $65.00 to $60.00 in a research report on Wednesday, July 29th. Finally, Canaccord Genuity Group lowered their target price on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $65.93.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter revenue of $5.138 billion, up 1.5% year over year and ahead of analysts’ expectations of approximately $5.06 billion. Adjusted EPS of $0.73 also narrowly exceeded the $0.72 consensus estimate. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: The company highlighted operational progress, including enrollment in the Elite AF clinical trial and FDA 510(k) clearances for StoneSmart technologies and an expanded SEISMIQ catheter offering. Cardiovascular sales rose 1.9% on a reported basis, while Latin American sales increased 16%. Boston Scientific Reports third-quarter sales
• Neutral Sentiment: Management’s results extended Boston Scientific’s streak of quarterly earnings beats, but the underlying growth rate remains modest. Revenue increased from $5.065 billion a year earlier, while regional performance was uneven, including a 0.6% decline in Asia-Pacific sales. Boston Scientific Q3 adjusted earnings
• Negative Sentiment: Boston Scientific again lowered its fiscal 2026 outlook, now targeting approximately 4.25% reported net-sales growth. Management expects fourth-quarter reported and organic sales to decline 1% to 3%, signaling a difficult finish to the year. Boston Scientific cuts view after cyberattack
• Negative Sentiment: The cybersecurity incident has disrupted business operations and weighed on the company’s forecast. Investors appear to be treating the reduced guidance as more important than the quarterly beat, raising concerns about near-term execution and the duration of the incident’s financial impact. Boston Scientific cybersecurity attack weighs on guidance
• Negative Sentiment: Profitability also weakened year over year: GAAP EPS fell to $0.40 from $0.51, while adjusted EPS declined from $0.75 to $0.73. The combination of lower earnings, cybersecurity-related uncertainty and another outlook reduction explains the negative investor reaction. Boston Scientific Q3 2026 earnings

Insider Buying and Selling

In related news, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig purchased 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 194,522 shares of company stock worth $9,385,210 in the last ninety days. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.